Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 14.02.2008 » TB-vaccine collaboration between Sanofi Pasteur and Statens Serum Institut (SSI) including Intercell´s adjuvant IC31® » World-leading Tuberculosis ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 06.02.2008 » Data from 50 patients reveal statistically significant viral load reduction and favorable safety profile » Data confirm findings from Interim Analysis from Q3 2007 » Further ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 16.01.2008 » Successfully passed inspection by the Medicines and Healthcare products Regulatory Agency (MHRA) » Intercell receives Manufacturer´s Licence for its site in Livingston, ...
» Malaria vaccine candidates selected by the PATH Malaria Vaccine Initiative will be formulated with ICLLs adjuvant IC31® » The project, funded by PATH, will evaluate the potency of Intercell´s novel adjuvant IC31® in the field of malaria ots.CorporateNews transmitted by euro adhoc. The issuer ...
» Intercell (ICLL) published pre-clinical data on its pneumococcal vaccine program in the renowned Journal of Experimental Medicine » The article reveals the Pneumococcal ANTIGENome determined by Intercell´s proprietary AIP® technology » The authors describe the selection process to retrieve highly ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Wien (euro adhoc) - Washington, DC and Vienna, Austria, December 20, 2007 - Today, December 20, 2007 Intercell AG (VSE, "ICLL") announced the finalization of the submission of a Biologics ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.12.2007 Vienna (Austria), December 20, 2007 - Intercell AG (VSE: ICLL) announced today that after having submitted the Market Authorization Application in Europe earlier this month it has ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 16.12.2007 Vienna (Austria), December 16th 2007 - Intercell AG (VSE: ICLL) today announced progress in its collaboration with Merck & Co., Inc. to develop a vaccine to prevent Staphylococcus ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 06.12.2007 » Intercell submitted MAA for its lead product, a vaccine against Japanese encephalitis » Product is intended to be licensed through centralized regulatory ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 04.12.2007 » SSI´s novel tuberculosis subunit vaccine HyVac4-IC31 (AERAS-404) enters phase I clinical trial in BCG-vaccinated individuals » The vaccine is a new ...
Intercell´s (ICLL) Phase III clinical trial results on its investigational Japanese Encephalitis vaccine have been published in the renowned medical journal The Lancet The article is the first publication describing the full clinical data to date on Intercell´s vaccine against Japanese Encephalitis The publication details significant safety and ...
» EUR 80 m upfront license and opt-in fee paid by Novartis » Development of key products within the Novartis alliance well on track » Actual cash position more than EUR 290 m ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. finances Wien (euro adhoc) - Vienna (Austria), November 23, 2007 - Intercell AG announced the completion of the next step in ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. quaterly report 19.11.2007 Vienna (Austria), November 19, 2007 - Today, vaccine company Intercell AG (VSE: ICLL) announced its financial results for the third quarter 2007, and presented an ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. shares Wien (euro adhoc) - Vienna (Austria), September 28, 2007 - Following the completion of a capital increase of 4.8 million shares, which were sold to Novartis Pharma AG at an issue price of EUR ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.08.2007 Vienna (Austria), August 30, 2007 - The management board of Intercell AG today resolved, subject to the approval of the supervisory board, to issue 4.8 million new shares of common ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 20.08.2007 »First data from 25 patients reveals statistically significant viral load reduction and very good safety profile »Data opens door for therapeutic ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 13.08.2007 Vienna (Austria), August 13, 2007 - Today Intercell AG (VSE: ICLL) announced the financial results for H1 2007 and an update on the company´s development programs ...
Total number of voting rights announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Intercell AG hereby announces that at the end of the month July 2007 the number of voting rights amounts to a total of 40.721.707 voting rights. The change of total voting ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 16.07.2007 » Development process for vaccine launch in endemic countries accelerated - First child vaccinated with IC51 » First administration of Intercell´s JE ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 02.07.2007 Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell to receive upfront payment of EUR 270 ($ 360) million in ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 18.06.2007 » Phase I clinical trial for a superior seasonal Influenza vaccine formulated with IC31TM started » The vaccine will be tested in three different dose ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 18.05.2007 Vienna (Austria), May 18, 2007 - Intercell AG (VSE, "ICLL") has been informed by its strategic partner Merck & Co., Inc. on the results of a Phase I study ...
Adjuvant IC31TM opens attractive new market opportunity in Flu All development projects on track Strong focus on nosocomial infections Net loss further decreased Strong financial position ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. finances Wien (euro adhoc) - IC31TM - Clinical ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. quaterly report 14.05.2007 IC31TM - Clinical results emphasize broad and commercial use in vaccine development » Protective profile for IC31TM in Phase I Tuberculosis vaccine trial - strong ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. annual report 27.04.2007 Following a successful year, Intercell AG (VSE, "ICLL") today presents its Annual Report 2006. The illustrated Annual Report contains the audited consolidated financial statements according to IFRS and gives detailed ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 04.04.2007 » Development process for vaccine launch in endemic countries accelerated - Approval for start of clinical trials in India obtained » First ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 14.03.2007 » The Danish Statens Serum Institut (SSI) and Intercell report promising data from a phase I clinical trial with a tuberculosis (TB) subunit vaccine » ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 05.03.2007 A strong and solid financial position at year end 2006 for further growth » Technologies created significant value - revenues of EUR 23.5 million, an increase of 176.5 percent - ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Wien (euro adhoc) - » 100 % of Pelias shares acquired in an all-share deal; former shareholders of Pelias receive 349,815 new Intercell shares from capital increase » Intercells product portfolio strengthened by clinical stage Pseudomonas vaccine candidate ¬ - focus on expanding Intercells leading ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 19.12.2006 Vienna (Austria), December 19, 2006 - Intercell AG (VSE, "ICLL") has been informed by its strategic partner Merck & Co., Inc. that a Phase I study of a recombinant subunit vaccine to ...